**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 61826

**Manuscript Type:** META-ANALYSIS

**Hepatitis E in solid organ transplant recipients: A systematic review and meta-analysis**

Hansrivijit P *et al*. HEV infection in SOTs

Panupong Hansrivijit, Angkawipa Trongtorsak, Max M Puthenpura, Boonphiphop Boonpheng, Charat Thongprayoon, Karn Wijarnpreecha, Avishek Choudhury, Wisit Kaewput, Shennen A Mao, Michael A Mao, Caroline C Jadlowiec, Wisit Cheungpasitporn

**Panupong Hansrivijit,** Department of Internal Medicine, UPMC Pinnacle, Harrisburg, PA 17104, United States

**Angkawipa Trongtorsak,** Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, IL 60202, United States

**Max M Puthenpura,** Department of Medicine, Drexel University College of Medicine, Philadelphia, PA 19129, United States

**Boonphiphop Boonpheng,** David Geffen School of Medicine, University of California, Los Angeles, Division of Nephrology, Los Angeles, CA 90095, United States

**Charat Thongprayoon,** Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Karn Wijarnpreecha,** Department of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, United States

**Avishek Choudhury,** School of Systems and Enterprises, Stevens Institute of Technology, Hoboken, NJ 07030, United States

**Wisit Kaewput,** Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok 10400, Thailand

**Shennen A Mao,** Department of Transplant Surgery, Mayo Clinic, Jacksonville, FL 32224, United States

**Michael A Mao,** Department of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, United States

**Caroline C Jadlowiec,** Department of Transplant Center, Mayo Clinic, Scottsdale, AZ 85259, United States

**Wisit Cheungpasitporn,** Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States

**Author contributions:** Hansrivijit P, Trongtorsak A, Puthenpura MM, Boonpheng B and Thongprayoon C performed acquisition of data; Hansrivijit P, Trongtorsak A, Puthenpura MM and Boonpheng B drafted the article; Hansrivijit P performed analysis and interpretation of data; Trongtorsak A performed analysis of data; Wijarnpreecha K, Choudhury A, Kaewput W, Mao SA, Mao MA, Jadlowiec CC and Cheungpasitporn W performed interpretation of data, revising the article; all authors were involved in the final approval.

**Corresponding author: Wisit Cheungpasitporn, FACP, Assistant Professor,** Department of Medicine, Mayo Clinic, 200 1st street SW, Rochester, MN 55905, United States. wcheungpasitporn@gmail.com

**Received:** December 19, 2020

**Revised:** January 17, 2021

**Accepted:** March 12, 2021

**Published online:** March 28, 2021

**Abstract**

BACKGROUND

Hepatitis E virus (HEV) infection is underdiagnosed due to the use of serological assays with low sensitivity. Although most patients with HEV recover completely, HEV infection among patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy can result in decompensated liver disease and death.

AIM

To demonstrate the prevalence of HEV infection in solid organ transplant (SOT) recipients.

METHODS

We searched Ovid MEDLINE, EMBASE, and the Cochrane Library for eligible articles through October 2020. The inclusion criteria consisted of adult patients with history of SOT. HEV infection is confirmed by either HEV-immunoglobulin G, HEV-immunoglobulin M, or HEV RNA assay.

RESULTS

Of 563 citations, a total of 22 studies (*n* = 4557) were included in this meta-analysis. The pooled estimated prevalence of HEV infection in SOT patients was 20.2% [95% confidence interval (CI): 14.9-26.8]. The pooled estimated prevalence of HEV infection for each organ transplant was as follows: liver (27.2%; 95%CI: 20.0-35.8), kidney (12.8%; 95%CI: 9.3-17.3), heart (12.8%; 95%CI: 9.3-17.3), and lung (5.6%; 95%CI: 1.6-17.9). Comparison across organ transplants demonstrated statistical significance (Q = 16.721, *P* = 0.002). The subgroup analyses showed that the prevalence of HEV infection among SOT recipients was significantly higher in middle-income countries compared to high-income countries. The pooled estimated prevalence of de novo HEV infection was 5.1% (95%CI: 2.6-9.6) and the pooled estimated prevalence of acute HEV infection was 4.3% (95%CI: 1.9-9.4).

CONCLUSION

HEV infection is common in SOT recipients, particularly in middle-income countries. The prevalence of HEV infection in lung transplant recipients is considerably less common than other organ transplants. More studies examining the clinical impacts of HEV infection in SOT recipients, such as graft failure, rejection, and mortality are warranted.

**Key Words:** Hepatitis E virus; Hepatitis E virus infection; Solid organ transplant; Prevalence

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Hansrivijit P, Trongtorsak A, Puthenpura MM, Boonpheng B, Thongprayoon C, Wijarnpreecha K, Choudhury A, Kaewput W, Mao SA, Mao MA, Jadlowiec CC, Cheungpasitporn W. Hepatitis E in solid organ transplant recipients: A systematic review and meta-analysis. *World J Gastroenterol* 2021; 27(12): 1240-1254

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i12/1240.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i12.1240

**Core Tip:** Hepatitis E virus (HEV) infection among patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy can result in decompensated liver disease and death. The prevalence of HEV infection in solid organ transplant (SOT) recipients varies by countries and transplanted organs. This meta-analysis, demonstrates the prevalence of HEV infection in SOT recipients is 20.3% (highest in liver transplant recipients and lowest in lung transplant recipients). The prevalence of HEV infection is two-fold more common in middle-income countries compared to high-income countries. Our findings encourage future studies to describe the clinical impacts of HEV infection on patient and allograft outcomes.

**INTRODUCTION**

Hepatitis E virus (HEV) results in approximately 20 million infections each year[1]. This virus is endemic to mostly developing countries in Asia, Africa, and Central America. There are additional cases of the disease manifesting in developed countries without patients having traveled to endemic areas[1,2]. As HEV is transmitted by the fecal-oral route, infection is more prevalent in areas with poor water quality and food contamination[1]. Patients typically demonstrate symptoms of fevers, gastrointestinal complaints, and jaundice within weeks of infection that self-resolve with supportive care[1]. Although most patients with HEV recover completely, HEV infection among patients with pre-existing chronic liver disease, pregnant women and organ-transplant recipients on immunosuppressive therapy can result in fulminant hepatitis with a 10%-30% mortality rate[3].

HEV has been noted to impact solid organ transplant (SOT) recipient outcomes. HEV infection has been cited to cause graft cirrhosis and subsequent failure in liver graft recipients secondary to chronic infection[4]. Furthermore, heart transplant recipients have been noted to have secondary liver infection and subsequent fibrosis[5]. In contrast, renal transplant allografts were found to have similar rejection and two-year graft survival between HEV seropositive and negative recipients, thus demonstrating HEV does not always impact non-liver allografts[6]. HEV reactivation from infected SOT allografts remains a risk as well, with case reports describing this occurrence in liver transplant recipients who receive an allograft with latent disease[7]. However, little evidence has demonstrated cases of HEV reactivation in renal transplant patients[7]. HEV viremia has also been found in non-SOTs such as hematopoietic stem cell transplant[8]. This suggests possible transmission of the virus through bone marrow products as well as SOT. Once infected with the virus, transplant recipients are at risk for developing chronic liver disease, especially with HEV genotype 3[9].

With the majority of this evidence being limited to case reports and some retrospective studies, there is very limited conclusive evidence illustrating the true HEV association, its related risk profile, and the clinical outcomes in transplant patients. Pooling the aggregate data of current studies will help elucidate the extent of risk and help stratify the clinical outcomes. We conducted this systematic review and meta-analysis to describe the prevalence of HEV infection in SOT patients. Our study is the first meta-analysis to emphasize the burden of HEV infection in SOT recipients.

**MATERIALS AND METHODS**

***Search strategy***

This manuscript follows the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA)[10] statement as well as Meta-analysis of Observational Studies in Epidemiology (MOOSE)[11] guidelines. A systematic search was conducted through the Ovid MEDLINE, EMBASE, and Cochrane Library from database inception to October 2020 using the following search terms: (“hepatitis E” OR “HEV”) AND (“transplant” OR “transplantation”) AND (“outcome\*” OR “mortality” OR “graft loss” OR “graft function” OR “incidence” OR “death”). The detailed search strategy for each database is summarized in Supplementary search strategy. No language restrictions were applied.

***Inclusion criteria***

The eligibility of each study was determined by the following inclusion criteria: (1) the nature of study is observational or conference abstract; (2) study population consisted of SOT recipients; and (3) the prevalence of HEV infection was reported as one of the outcomes of interest. Exclusion criteria consisted of pediatric patients, hematopoietic stem cell transplant recipients, and studies with a total sample size of less than 50 patients. The latter was to avoid inter-study variance. Study eligibility was independently evaluated by two investigators (PH and AT). Any disagreements were resolved by mutual consensus. The quality of each study was appraised using the Newcastle–Ottawa quality scale[12], which assesses six components including (1) representativeness of the subjects; (2) ascertainment of the exposure; (3) demonstration of outcome of interest was not present at start of study; (4) assessment of outcome; (5) follow-up duration period was long enough for outcome to occur; and (6) adequate follow-up duration.

***Review process and data extraction***

The titles and abstracts of all discovered studies were screened (PH and AT) prior to a full-text review. The full-text of the screened articles was reviewed to determine their eligibility for inclusion into the systematic review and meta-analysis. We created a standardized data collection form to extract the following information from the included studies: First author’s name, year of publication, country of origin, study design, subject(s), sample size, transplanted organ (heart, lung, liver, kidney, and undifferentiated), age, male sex, ethnicity, prevalence of HEV, confirmatory test used to diagnose HEV infection, prevalence of acute HEV infection, death, other reported outcomes and follow-up duration. Country of research origin was classified into high-income and middle-income based on the definition by the World Bank[12]. De novo HEV infection is defined by post-transplant HEV infection in patients with negative pre-transplant HEV-immunoglobulin G (IgG), HEV-immunoglobulin M (IgM) or HEV-RNA. Acute HEV infection is determined by positive post-transplant HEV-IgM with or without positive HEV-RNA.

***Measurements***

The prevalence of HEV infection, prevalence of de novo HEV infection, and prevalence of acute HEV infection underwent meta-analysis and the results were reported in percentage along with 95% confidence interval (CI). Forest plot of each analysis was created. Results were presented in percentage for categorical data and in mean ± standard deviation (SD) or median (interquartile range) for continuous data.

***Network association***

The prevalence of HEV infection in each organ transplant (heart, lung, liver, kidney, and undifferentiated) were individually compared using mixed-effects model. The association of each couple comparison was assessed with Cochrane’s *Q*-test and its *P* value. *P* values less than 0.05 were considered statistically significant.

***Subgroup analysis, meta-regression analysis, and publication bias***

Subgroup analyses based on the following variables were performed: study year, country of origin, study design, sample size, mean age, male proportion, number of confirmatory tests used in the study, antibody assay, and follow-up duration. Mixed-effects model of analysis was used in subgroup analyses. Publication bias was evaluated by (1) funnel plot (if the total number of studies was greater than ten[13]); and (2) Egger’s regression intercept. An intercept *P* value of less than 0.05 was considered significant for potential publication bias. The quality of each study was appraised using the Newcastle-Ottawa quality scale[14].

***Statistical analysis***

All statistical analyses were performed by the Comprehensive Meta-analysis version 3 software (Eaglewood, NJ, United States) and SPSS version 23.0 (IBM Corp., Armonk, NY, United States). Statistical heterogeneity of the included studies was assessed using the Cochran's *Q*-test and *I2* statistics. An *I2* value of ≤ 25% represents insignificant heterogeneity, 25%-50% represents low heterogeneity, 50%-75% represents moderate heterogeneity, and > 75% represents high heterogeneity[15].For analyses with *I2*> 50%, the results were analyzed by random-effects model to minimize the heterogeneity and external variance[16]. A *P* value of less than 0.05 represents statistical significance.

**RESULTS**

***Study characteristics***

Of 563 citations, a total of 20 studies consisting of 5842 subjects were included in this meta-analysis and systematic review. Figure 1 provides a flowchart of the literature search and study selection for this meta-analysis. Included studies were published from 2011 to 2020. The study design was retrospective (66.7%) and prospective (33.3%). The median age was 52.0 (11.9) years, 68.5% were male, and 27.7% were Caucasian. The median duration of follow-up was 13.7 (14.0) mo.

***Prevalence of HEV infection***

For the prevalence of HEV infection, a total of 18 studies (*n* = 4557) were included in the meta-analysis. Erken *et al*[17] was excluded as the authors only reported the prevalence of de novo HEV infection while Reekie *et al*[18] was excluded because of the potential risk of bias. All other articles had acceptable NOS scores (low risk of bias) for inclusion into meta-analysis for prevalence of HEV infection.

The pooled estimated prevalence of HEV infection in SOT recipients was 20.2% (95%CI: 14.9-26.8; *I2* = 95.3%; Figure 2A). The pooled estimated prevalence of HEV infection in each transplanted organ was: Liver (27.2%; 95%CI: 20.0-35.8; *n* = 11; *n* = 1887), kidney (15.3%; 95%CI: 6.6-31.5; *n* = 4; *n* = 1137), heart (12.8 %; 95%CI: 9.3-17.3; *n* = 1; *n* = 274), lung (5.6%; 95%CI: 1.6-17.9; *n* = 3; *n* = 625), and undifferentiated (29.6%; 95%CI: 10.1-61.1; *n* = 3; *n* = 634).

***De novo HEV infection***

A total of seven studies (*n* = 2004) were included in the meta-analysis of de novo HEV infection. The pooled estimated prevalence of de novo HEV infection in SOT recipients was 5.1% (95%CI: 2.6-9.6; *I2* = 90.8%). The forest plot is illustrated in Figure 2B.

***Acute HEV infection***

A total of nine studies (*n* = 1925) were included in the meta-analysis of acute HEV infection. The pooled estimated prevalence of acute HEV infection in SOT recipients was 4.3% (95%CI: 1.9-9.4; *I2* = 90.7%). The forest plot is illustrated in Figure 2C.

***Network association analysis***

We used subgroup analysis to compare the pooled estimated prevalence of HEV infection from two solid organs of interest at a time. Figure 3 depicts a diagram of the network association analysis. In brief, the prevalence of HEV infection in lung transplant was significantly lower than liver transplant patients (Q = 7.033, *P* = 0.008) and undifferentiated patients (Q = 4.322, *P* = 0.038). There were no statistically significant associations across all other comparisons.

***Subgroup analyses***

Subgroup analysis results are depicted in Table 1. Here, we analyzed the pooled estimated prevalence of HEV infection based on study characteristics. We applied mixed-effects model to minimize inter-study variance in the subgroup analyses. In brief, we found that the pooled prevalence of HEV infection was similar after adjustment for study year (< 2015 *vs* ³2015), study design (prospective *vs* retrospective), sample size (< 400 *vs* ³400), age (£ 50 years *vs* > 50 years), male proportion (£ 65% *vs* > 65%), number of confirmatory tests (> 1 marker *vs* single marker), and follow-up duration (£ 12 mo *vs* > 12 mo). Interestingly, we found that the prevalence of HEV infection was significantly higher in middle-income countries compared to high-income countries (41.8% *vs* 18.9%; Q = 22.375, *P* < 0.001). The seroprevalence of positive anti-HEV antibodies was significantly higher in studies that utilized Wantai assay compared to studies with other assays (28.4% *vs* 12.3%; Q = 10.134, *P* = 0.001).

***Evaluation for publication bias***

The p-value of Egger’s regression intercept for the analysis of pooled total prevalence of HEV infection, de novo HEV infection and acute HEV infection was 0.060, 0.054, and 0.136, respectively. These values indicated no potential publication bias. The funnel plot for the HEV pooled prevalence infection analysis in undifferentiated SOT recipients is illustrated in Supplementary Figure 1.

***Systemic review***

Table 2 illustrates study characteristics and outcomes included in this systematic review. Kamar *et al*[19] showed that the use of tacrolimus (OR 1.89; 95%CI: 1.49-1.97) and low platelet count (OR 1.02; 95%CI: 1.00-1.10) were associated with chronic HEV infection in SOT patients. Additionally, cirrhosis (OR 7.6; 95%CI: 4.4-13.1), liver transplantation (OR 3.1; 95%CI: 1.8-5.4) and Human immunodeficiency virus (HIV) infection (OR 2.4; 95%CI: 1.3-4.4) were significant risk factors for HEV infection in the Spanish cohort[20]. Another study[21] demonstrated that HBV coinfection was associated with chronic HEV infection in SOT recipients (OR 7.4; 95%CI: 1.3-37.0), and patients with positive HEV-IgG had higher odds of developing hepatocellular carcinoma (OR 2.3; 95%CI: 1.1-4.8). Pischke *et al*[22] emphasized the prevalence of HEV infection in heart transplant patients by demonstrating that these patients had a significantly higher seroprevalence of HEV-IgG than healthy individuals. Interestingly, in a Chinese cohort of 408 Liver transplant recipients[23], alcoholic cirrhosis (OR 5.3; 95%CI: 1.4-21.0) and liver failure (OR 23.8; 95%CI: 2.8-203.1) were associated with increased de novo HEV infection during a follow-up of 3 years while graft rejection (OR 0.22; 95%CI: 0.06-0.74) was surprisingly a protective factor.

**DISCUSSION**

The meta-analysis revealed prevelance of HEV in SOT recipients is 20%. De novo HEV infection and acute HEV infection accounted for less than 5% of infections. A recent meta-analysis of 419 studies comprised of 519,872 individuals showed an estimated global seroprevalence of anti-HEV IgG of 12.5% and a pooled estimated anti-HEV IgM seroprevalence of 1.5%[24]. Although our study did not provide a direct comparison to non-transplant patients, it can be extrapolated that the prevalence of HEV infection is higher in SOT patients (20.1% *vs* 12.5%). The prevalence of acute HEV infection was also higher in SOT patients compared to non-transplant patients (4.3% *vs* 1.5%). These findings emphasize the burden of HEV infection in SOT patients. To date, the United States has not issued national guidelines for the management of hepatitis E in SOT. However, recent guidelines from the British Transplantation Society have recommended screening for HEV infection in individuals with elevated liver enzymes (evidence 1D)[25]. Unfortunately, the evidence for this recommendation is relatively weak due to a lack of studies supporting the association between HEV infection and adverse post-transplant clinical outcomes. More studies on this particular topic are needed. Furthermore, our study indicated a high burden of de novo HEV infection and acute HEV infection in SOT patients. Whether these infections affect the post-transplant clinical outcomes different from chronic HEV infection is yet to be investigated.

It is possible that the seroprevalence of anti-HEV IgG could be affected by the assays used for antibody testing. Rossi-Tamisier *et al*[26] compared the positive rates of two different commercial microplate enzyme-immunoassays and found that the prevalence of seropositive IgG against HEV was higher in the Wantai assay compared to Adaltis assay[26]. Similarly, Li *et al*[24] conducted a meta-analysis and described that the seroprevalence of anti-HEV IgG was highest with the Wantai assay in comparison with other commercial assays[24]. In our subgroup analysis, we also observed that the seroprevalence of anti-HEV antibodies from studies that utilized the Wantai assay was significantly higher than other assays. Thus, the type of assay test should be taken into consideration when interpreting positive anti-HEV IgG or IgM results.

We also found that the prevalence of HEV infection was significantly higher in middle-income countries *vs* high-income countries. This finding is consistent with previously published. Li *et al*[24] suggested that the seroprevalence of anti-HEV IgG was at least two-fold higher in Africa and Asia in comparison to Europe and North America[24]. As HEV route of transmission *via* the fecal-oral route is similar to hepatitis A virus, patients with poor hygiene are predisposed to both hepatitis A and hepatitis E infection. Consumption of raw meat, exposure to soil, contact with dogs, residing in rural areas, and an education level attained less than elementary school is known risk factors for HEV infection[24]. However, our study did not include any articles that originated from low-income countries where the prevalence of HEV infection is anticipated to be high. This may be due to the lower rate of SOTs within this demographic. More studies from low- and middle-income countries are encouraged to reliably determine the global burden of HEV infection in SOT recipients.

We found that the prevalence of HEV infection was lowest in lung transplant recipients. It is unclear why lung transplant recipients had less HEV infection compared with liver transplant recipients. It is possible that the prevalence of HEV infection in lung transplant recipients is under-reported in the literature, given the smaller number of lung transplants annually, at least in the United States. The total number of lung transplants is three times fewer than the total number of liver transplants from the United States Organ Procurement and Transplantation Network[27]. However, it is also possible that lung transplant recipients may be predisposed to receiving ribavirin therapy for other indications, such as respiratory syncytial virus or hepatitis C virus infection. Ribavirin and interferon-a are two main antivirals that have been used to treat cases of HEV infection. There are several reports of successful use of ribavirin in chronic HEV infection to achieve overall sustained virologic response of up to 80%[28-30]. The underlying mechanism by which lung transplant patients had lower HEV infection should be investigated in future clinical studies.

Several risk factors for HEV infection in SOT patients have been identified from our systematic review. The use of tacrolimus (versus cyclosporine), low platelet count, cirrhosis, liver failure, human immunodeficiency virus (HIV) coinfection, and hepatitis B virus (HBV) coinfection are all significant risk factors for HEV infection. Hypothetically, tacrolimus generally delivers more immunosuppressive property than cyclosporine, which could predispose patients to contract HEV. This statement, however needs more supporting clinical evidence. Liver disease and associated manifestations including cirrhosis, liver failure, and low platelet count, are not specific to HEV infection; they may be attributed to HEV infection or one of many other etiologies of chronic liver failure. HIV and HBV coinfection raises concern for transfusion-associated HEV transmission, which has been reported in several studies worldwide[31-34].

Our study is subjected to certain limitations. First, all studies were observational in design, making them susceptible to selection bias. We attempted to minimize this bias by performing risk of bias assessment prior to inclusion of studies into our meta-analysis and systematic review. Second, the clinical impact of HEV infection was not meta-analyzed due to limited information from the original articles. More studies investigating the association between HEV infection and clinical outcomes are needed. Third, the genotype of HEV was not reported. Although it is well perceived that HEV genotype 3 and 4 are more common in immunocompromised patients[2], the prevalence of HEV genotype 3 and 4 infection in SOT patients remains inconclusive from our study. Fourth, only the status of recipients was evaluated in our study. HEV infection profile in donors was not taken into consideration due to the limited data in the original articles. HEV transmission *via* transplanted liver has been reported and would potentially impact the prevalence of HEV infection in the recipients. Fifth, generalization of our findings to heart transplant patients is limited because only one study included heart transplant patients. Finally, the majority of included studies were from high-income countries. Additional cohorts from low-income and middle-income countries are highly encouraged.

The future prospects include evaluation of the impact of HEV on SOT patients and graft analysis by meta-analysis or meta-regression analysis. Once the association between HEV infection and adverse clinical outcomes is conclusive, the role of ribavirin therapy for HEV eradication should be investigated in future clinical trials. The ultimate objective of this study is to help contribute to the core knowledge of improving the clinical outcomes of SOT recipients.

**CONCLUSION**

In conclusion, HEV infection is common in SOT recipients and accounts for 20.2%. It is at least two-fold higher in middle-income countries compared to high-income countries. The prevalence of HEV infection in lung transplant recipients is considerably less common than other organ transplants. More studies demonstrating the clinical impacts of HEV infection in SOT recipients, such as graft failure, rejection, and mortality, are warranted.

**ARTICLE HIGHLIGHTS**

***Research background***

Hepatitis E virus (HEV) infection among patients with pre-existing chronic liver disease and organ-transplant recipients on immunosuppressive therapy can result in decompensated liver disease and death.

***Research motivation***

The prevalence of HEV infection in solid organ transplant (SOT) recipients varies from one organ to another. The disease burden and clinical outcomes of HEV infection in such patients are under-investigated.

***Research objectives***

To demonstrate the prevalence of HEV infection in SOT recipients.

***Research methods***

Eligible articles were searched through Ovid MEDLINE, EMBASE, and the Cochrane Library. The inclusion criteria are adult patients with history of SOT. HEV infection is confirmed by either HEV-immunoglobulin G, HEV-immunoglobulin M, or HEV RNA assay.

***Research results***

Of 563 citations, a total of 22 studies (*n* = 4557) were included in the meta-analysis. The pooled estimated prevalence of HEV infection in SOT patients was 20.2% (95%CI: 14.9-26.8). The pooled estimated prevalence of HEV infection in each organ transplant was as followed: liver (27.2%; 95%CI: 20.0-35.8), kidney (12.8%; 95%CI: 9.3-17.3), heart (12.8%; 95%CI: 9.3-17.3), and lung (5.6%; 95%CI: 1.6-17.9). The comparison across all organ transplant was statistically significant (Q = 16.721, *P* = 0.002). The subgroup analyses showed that the prevalence of HEV infection among SOT recipients was significantly higher in middle-income countries compared to high-income countries. The pooled estimated prevalence of de novo HEV infection was 5.1% (95%CI: 2.6-9.6) and the pooled estimated prevalence of acute HEV infection was 4.3% (95%CI: 1.9-9.4).

***Research conclusions***

HEV infection is common in SOT recipients, especially in middle-income countries. The prevalence of HEV infection in lung transplant recipients is considerably less common than other organ transplants.

***Research perspectives***

The results of this study offer a preliminary perspective on the magnitude of disease burden from HEV infection, especially in middle-income countries. In the future, large-scale observational studies investigating these associations between HEV infection, patient outcomes, and allograft outcomes are needed to help guide the management of HEV infection in SOT recipients. We also highlight the need for studies from low-income and middle-income countries, as the prevalence of HEV infection from these countries is under-reported.

**REFERENCES**

1 **Webb GW**, Dalton HR. Hepatitis E: an underestimated emerging threat. *Ther Adv Infect Dis* 2019; **6**: 2049936119837162 [PMID: 30984394 DOI: 10.1177/2049936119837162]

2 **Whitsett M**, Feldman DM, Jacobson I. Hepatitis E Virus Infection in the United States: Current Understanding of the Prevalence and Significance in the Liver Transplant Patient Population and Proposed Diagnostic and Treatment Strategies. *Liver Transpl* 2020; **26**: 709-717 [PMID: 32061053 DOI: 10.1002/lt.25732]

3 **Patra S**, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. *Ann Intern Med* 2007; **147**: 28-33 [PMID: 17606958 DOI: 10.7326/0003-4819-147-1-200707030-00005]

4 **Aggarwal A**, Perumpail RB, Tummala S, Ahmed A. Hepatitis E virus infection in the liver transplant recipients: Clinical presentation and management. *World J Hepatol* 2016; **8**: 117-122 [PMID: 26807207 DOI: 10.4254/wjh.v8.i2.117]

5 **Koning L**, Pas SD, de Man RA, Balk AH, de Knegt RJ, ten Kate FJ, Osterhaus AD, van der Eijk AA. Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. *J Heart Lung Transplant* 2013; **32**: 78-85 [PMID: 23260707 DOI: 10.1016/j.healun.2012.10.008]

6 **Lim MA**, Kamili S, Cohen JB, Green-Montfort T, Tejada-Strop A, Kohli J, Drobeniuc J, Patel P, Vanderveen M, Bloom RD. Hepatitis E Virus Infection in Kidney Transplant Patients: A Single-Center Study. *Transplantation* 2018; **102**: e126-e127 [PMID: 29329183 DOI: 10.1097/TP.0000000000002071]

7 **Schlosser B**, Stein A, Neuhaus R, Pahl S, Ramez B, Krüger DH, Berg T, Hofmann J. Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. *J Hepatol* 2012; **56**: 500-502 [PMID: 21798217 DOI: 10.1016/j.jhep.2011.06.021]

8 **Ian R,** Fox T, Irish D, Bharucha T, Thorburn D, Mark H, Mackinnon S, Richard T, Ijaz S, Sekhar M. Hepatitis E Viraemia in Transplant Recipients. Blood 2016; 128(22): 3846-3846 [DOI: 10.1182/blood.V128.22.3846.3846]

9 **Behrendt P**, Steinmann E, Manns MP, Wedemeyer H. The impact of hepatitis E in the liver transplant setting. *J Hepatol* 2014; **61**: 1418-1429 [PMID: 25195557 DOI: 10.1016/j.jhep.2014.08.047]

10 **Moher D**, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**: e1000097 [PMID: 19621072 DOI: 10.1371/journal.pmed.1000097]

11 **Stroup DF**, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000; **283**: 2008-2012 [PMID: 10789670 DOI: 10.1001/jama.283.15.2008]

12 **World Bank Country and Lending Groups.** [Cited December 5, 2020]. Available from: https//datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups

13 **Easterbrook PJ**, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. *Lancet* 1991; **337**: 867-872 [PMID: 1672966 DOI: 10.1016/0140-6736(91)90201-y]

14 **Stang A**. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**: 603-605 [PMID: 20652370 DOI: 10.1007/s10654-010-9491-z]

15 **Higgins JP**, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003; **327**: 557-560 [PMID: 12958120 DOI: 10.1136/bmj.327.7414.557]

16 **Schroll JB**, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. *BMC Med Res Methodol* 2011; **11**: 22 [PMID: 21349195 DOI: 10.1186/1471-2288-11-22]

17 **Erken R,** Willemse S, Sinnige M, Reesink H, Bemelman F, Zaaijer H. Incidence of hepatitis E infection in renal transplant patients in The Netherlands. *J Hepatol* 2018; **68:** S757-S759 [DOI: 10.1016/S0168-8278(18)31782-3]

18 **Reekie I**, Irish D, Ijaz S, Fox T, Bharucha T, Griffiths P, Thorburn D, Harber M, MacKinnon S, Sekhar M. Hepatitis E infection in stem cell and solid organ transplantpatients: A cross-sectional study: The importance of HEV RNA screening in peri-transplant period. *J Clin Virol* 2018; **107**: 1-5 [PMID: 30099145 DOI: 10.1016/j.jcv.2018.07.011]

19 **Kamar N,** Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E, Conti F, Lebray P, Dalton HR, Izopet J, Rostaing L. Predictive factors, natural history and outcome of chronic hepatitis e virus infection in solid-organ-transplant patients: A retrospective multicenter study. *Am J Transplant* 2011; 11.

20 **Riveiro-Barciela M**, Buti M, Homs M, Campos-Varela I, Cantarell C, Crespo M, Castells L, Tabernero D, Quer J, Esteban R, Rodriguez-Frías F. Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection. *PLoS One* 2014; **9**: e103028 [PMID: 25068388 DOI: 10.1371/journal.pone.0103028]

21 **Crossan C,** Dalton H, Scobie L, Simpson K, Davidson J. Hepatitis E and Scottish liver transplant recipients.*J Viral Hepat* 2014; **20:** 41 [DOI: 10.1111/jvh.12166\_46]

22 **Pischke S,** Stiefel P, Franz B, Bremer B, Bara CL. Chronic hepatitis e in heart transplant recipients. *Am J Transplant* 2012; **12:** 3128-3133 [DOI: 10.1111/j.1600-6143.2012.04200.x]

23 **Wang Y.** Prevalence and risk factors of De novo HEV infection in solid organ transplant patients. Hepatology International Conference: 29th Annual Conference of Asian Pacific Association for the Study of the Liver Indonesia 2020.

24 **Li P**, Liu J, Li Y, Su J, Ma Z, Bramer WM, Cao W, de Man RA, Peppelenbosch MP, Pan Q. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. *Liver Int* 2020; **40**: 1516-1528 [PMID: 32281721 DOI: 10.1111/liv.14468]

25 **McPherson S**, Elsharkawy AM, Ankcorn M, Ijaz S, Powell J, Rowe I, Tedder R, Andrews PA. Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. *Transplantation* 2018; **102**: 15-20 [PMID: 28795981 DOI: 10.1097/TP.0000000000001908]

26 **Rossi-Tamisier M**, Moal V, Gerolami R, Colson P. Discrepancy between anti-hepatitis E virus immunoglobulin G prevalence assessed by two assays in kidney and liver transplant recipients. *J Clin Virol* 2013; **56**: 62-64 [PMID: 23089569 DOI: 10.1016/j.jcv.2012.09.010]

27 **Singh N**. Infections in Solid-Organ Transplant Recipients. *Am J Infect Control* 1997 [DOI: 10.1016/S0196-6553(97)90089-4]

28 **Kamar N**, Izopet J, Tripon S, Bismuth M, Hillaire S, Dumortier J, Radenne S, Coilly A, Garrigue V, D'Alteroche L, Buchler M, Couzi L, Lebray P, Dharancy S, Minello A, Hourmant M, Roque-Afonso AM, Abravanel F, Pol S, Rostaing L, Mallet V. Ribavirin for chronic hepatitis E virus infection in transplant recipients. *N Engl J Med* 2014; **370**: 1111-1120 [PMID: 24645943 DOI: 10.1056/NEJMoa1215246]

29 **Shrestha A**, P Gupta B, K Lama T. Current Treatment of Acute and Chronic Hepatitis E Virus Infection: Role of Antivirals. *Euroasian J Hepatogastroenterol* 2017; **7**: 73-77 [PMID: 29201777 DOI: 10.5005/jp-journals-10018-1216]

30 **Kamar N**, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, Cointault O, Ribes D, Nogier MB, Alric L, Peron JM, Izopet J. Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. *Gastroenterology* 2010; **139**: 1612-1618 [PMID: 20708006 DOI: 10.1053/j.gastro.2010.08.002]

31 **Kimura Y**, Gotoh A, Katagiri S, Hoshi Y, Uchida S, Yamasaki A, Takahashi Y, Fukutake K, Kiguchi T, Ohyashiki K. Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes. *Blood Transfus* 2014; **12**: 103-106 [PMID: 24120594 DOI: 10.2450/2013.0081-13]

32 **Mitsui T**, Tsukamoto Y, Yamazaki C, Masuko K, Tsuda F, Takahashi M, Nishizawa T, Okamoto H. Prevalence of hepatitis E virus infection among hemodialysis patients in Japan: evidence for infection with a genotype 3 HEV by blood transfusion. *J Med Virol* 2004; **74**: 563-572 [PMID: 15484278 DOI: 10.1002/jmv.20215]

33 **Boxall E**, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S, Teo CG. Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. *Transfus Med* 2006; **16**: 79-83 [PMID: 16623913 DOI: 10.1111/j.1365-3148.2006.00652.x]

34 **Colson P**, Coze C, Gallian P, Henry M, De Micco P, Tamalet C. Transfusion-associated hepatitis E, France. *Emerg Infect Dis* 2007; **13**: 648-649 [PMID: 17561564 DOI: 10.3201/eid1304.061387]

35 **Legrand-Abravanel F**, Kamar N, Sandres-Saune K, Lhomme S, Mansuy JM, Muscari F, Sallusto F, Rostaing L, Izopet J. Hepatitis E virus infection without reactivation in solid-organ transplant recipients, France. *Emerg Infect Dis* 2011; **17**: 30-37 [PMID: 21192851 DOI: 10.3201/eid1701.100527]

36 **Mallet V,** Roque-Afonso AM, Sberro R, Vallet-Pichard A, Deau B, Portal A, Hauser L, Legendre CM, Pol S. Therapeutic plasma exchange as a method of transmission of Hepatitis E Virus in solid organ transplant recipients. Hepatology Conference: 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013; 58.

37 **Pischke S**, Greer M, Hardtke S, Bremer B, Gisa A, Lehmann P, Haverich A, Welte T, Manns MP, Wedemeyer H, Gottlieb J; Hepatitis E study group. Course and treatment of chronic hepatitis E virus infection in lung transplant recipients. *Transpl Infect Dis* 2014; **16**: 333-339 [PMID: 24438577 DOI: 10.1111/tid.12183]

38 **Riezebos-Brilman A,** Puchhammer-Stöckl E, van der Weide HY, Haagsma EB, Jaksch P, Bejvl I, Niesters HG, Verschuuren EA. Chronic hepatitis e infection in lung transplant recipients. *J Heart Lung Transplant* 2013; **32:** 341-346 [PMID: 23415316 DOI: 10.1016/j.healun.2012.11.027]

39 **Abravanel F**, Lhomme S, Chapuy-Regaud S, Mansuy JM, Muscari F, Sallusto F, Rostaing L, Kamar N, Izopet J. Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. *J Infect Dis* 2014; **209**: 1900-1906 [PMID: 24436450 DOI: 10.1093/infdis/jiu032]

40 **Buffaz C**, Scholtes C, Dron AG, Chevallier-Queyron P, Ritter J, André P, Ramière C. Hepatitis E in liver transplant recipients in the Rhône-Alpes region in France. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 1037-1043 [PMID: 24445407 DOI: 10.1007/s10096-013-2042-2]

41 **De Nicola S,** Donato MF, Premoli C, Lunghi G, Bono P, Manini MA, Lampertico P, Malinverno F, Monico S, Reggiani P, Colombo M, Aghemo A. Prevalence and clinical impact of hepatitis E virus in immunosuppressed patient after liver transplantation. Hepatology Conference: 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015; 62

42 **Magnusson J**, Norder H, Riise GC, Andersson LM, Brittain-Long R, Westin J. Incidence of Hepatitis E Antibodies in Swedish Lung Transplant Recipients. *Transplant Proc* 2015; **47**: 1972-1976 [PMID: 26293083 DOI: 10.1016/j.transproceed.2015.04.092]

43 **Sherman KE,** Boyce CL, Rouster SD, Barin B, Terrault N, Kottilil S, Blackard J, Shata MTM. Longitudinal analysis of hepatitis e virus (HEV) in a U.S. cohort of HIV-infected liver and kidney transplant recipients. Hepatology Conference: 68th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2017; 66

44 **Samala NR,** Auh S, Abdullah K, Dakhoul L, Johnson J, Wright EC, Alter HJ, Lucey MR, Ghabril MS, Rangnekar AS, Reddy KR, Ghany MG. Prevalence and incidence of hepatitis e in organ waitlist and transplant recipients in the US. Hepatology Conference: 69th Annual Meeting of the American Association for the Study of Liver Diseases, AASLD 2018; 68

45 **Darstein F**, Häuser F, Mittler J, Zimmermann A, Lautem A, Hoppe-Lotichius M, Otto G, Lang H, Galle PR, Zimmermann T. Hepatitis E Is a Rare Finding in Liver Transplant Patients With Chronic Elevated Liver Enzymes and Biopsy-Proven Acute Rejection. *Transplant Proc* 2020; **52**: 926-931 [PMID: 32139278 DOI: 10.1016/j.transproceed.2020.01.011]

46 **Komolmit P**, Oranrap V, Suksawatamnuay S, Thanapirom K, Sriphoosanaphan S, Srisoonthorn N, Posuwan N, Thongmee T, Treeprasertsuk S, Poovorawan Y. Clinical significance of post-liver transplant hepatitis E seropositivity in high prevalence area of hepatitis E genotype 3: a prospective study. *Sci Rep* 2020; **10**: 7352 [PMID: 32355268 DOI: 10.1038/s41598-020-64551-x]

47 **Zanotto E**, Rittá M, Pittaluga F, Martini S, Ciotti M, Cavallo R, Costa C. Seroprevalence of Hepatitis E Virus in liver transplant patients in Turin, Italy. *Panminerva Med* 2020 [PMID: 32700882 DOI: 10.23736/S0031-0808.20.03877-X]

**Footnotes**

**Conflict-of-interest statement:** The authors declared no potential conflicts of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** December 19, 2020

**First decision:** January 10, 2021

**Article in press:** March 12, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Fallatah H **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 PRISMA flowchart of article search and selection.**

 

**Figure 2 Forest plots of meta-analysis.** A: The pooled prevalence of hepatitis E virus (HEV) infection (*I2* 95.3%; Egger’s intercept 0.060); B: The pooled prevalence of de novo HEV infection (*I2* 90.8%; Egger’s intercept 0.054); C: The pooled prevalence of acute HEV infection (*I2* 90.7%; Egger’s intercept 0.136). CI: Confidence interval; HEV: Hepatitis E virus.



**Figure 3 Network association analysis.** a*P* < 0.05; b*P* < 0.01.

**Table 1 Subgroup analyses of all variables**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Subgroup** | ***n* (%)** | **Incidence (%)** | **95%CI** |  |
| Year |  |  |  |  |
| < 2015 | 10 | 17.1 | 9.9-27.9 |  |
| ≥ 2015 | 8 | 26.8 | 19.5-35.7 | Q = 2.248, *P* = 0.134 |
| Country |  |  |  |  |
| High-income | 16 | 18.9 | 13.1-26.4 |  |
| Middle-income | 2 | 41.8 | 37.6-46.1 | Q = 22.375, *P* < 0.001c |
| Study type |  |  |  |  |
| Prospective | 6 | 22.3 | 13.4-34.7 |  |
| Retrospective | 12 | 20.3 | 12.8-30.7 | Q = 0.077, *P* = 0.782 |
| Sample size |  |  |  |  |
| *n* < 400 | 14 | 25.4 | 18.9-33.1 |  |
| *n* ≥ 400 | 4 | 10.4 | 3.2-28.8 | Q = 2.613, *P* = 0.106 |
| Mean age |  |  |  |  |
| ≤ 50 yr | 3 | 17.7 | 5.4-44.8 |  |
| > 50 yr | 10 | 20.2 | 13.4-29.3 | Q = 0.051, *P* = 0.821 |
| Male proportion |  |  |  |  |
| ≤ 65% | 7 | 16.0 | 7.7-30.4 |  |
| > 65% | 5 | 23.0 | 12.5-38.5 | Q = 0.631, *P* = 0.427 |
| Diagnostic test |  |  |  |  |
| More than one marker | 11 | 25.9 | 19-34.4 |  |
| Single marker | 7 | 14.1 | 5.5-31.5 | Q = 1.806, *P* = 0.179 |
| Antibody assay |  |  |  |  |
| Wantai assay | 8 | 28.4 | 21.4-36.6 |  |
| Other assays | 6 | 12.3 | 7.7-19.1 | Q = 10.134, *P* = 0.001b |
| Follow-up |  |  |  |  |
| ≤ 12 mo | 7 | 23.8 | 23.8 |  |
| > 12 mo | 4 | 26.8 | 26.8 | Q = 0.072, *P* = 0.789 |

b*P* < 0.01. c*P* < 0.001. CI: Confidence interval; *n*: Number of studies.

**Table 2** **Characteristics of studies included in the systematic review**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Country** | **Type** | ***n* (%)** | **Organ** | **Age** | **Male** | **White** | **HEV** | **Confirmed test** | **Acute HEV** | **Death** | **Outcome** | **Follow-up** |
| Kamar *et al*[19], 2011  | Monaco | R | 85 | UD | - | - | - | 65.9% (total; 56/85). 32.1% (18/85) had clearance. 0% (0/18) reactivation | Persistently elevated LFTs and positive HEV-RNA | 0% | - | Factors associated with chronic HEV infection: Tacrolimus (OR 1.89; 1.49-1.97). Low platelet (OR 1.02; 1.00-1.10) | 6 mo |
| Legrand-Abravanel *et al*[35], 2011  | France | R | 700 | Liver (*n* = 171), kidney (*n* = 529) | 52 | 65.6% | - | 15.1% (total; 106/700). 14.6% (25/171) for LTx. 15.3% (81/529 for KTx. 5.6% (de novo; 34/601). 0% (0/17) reactivation | Positive HEV IgG, IgM (Adaltis assay) or HEV-RNA | 2.8% (17/611). 2.7% (4/150) for LTx. 2.8% (13/461) for KTx | - | - | 22 mo |
| Pischke *et al*[22], 2012  | Germany | P | 274 | Heart | 57 | 80% | - | 12.8% (total; 35/274). 7.3% (de novo; 20/274) | Positive HEV IgG (MP assay) or HEV-RNA | - | - | Heart transplant recipients had significantly higher seroprevalence of HEV-IgG than healthy individuals | 8 mo |
| Crossan *et al*[21], 2014 | Scotland | P | 317 | UD | 56.4 | 93.4% | - | 14.2% (total; 45/317) | Positive HEV IgG or IgM (Wantai assay) | 0.9% (3/317) | - | Factors associated with chronic HEV infection: HBV coinfection (OR 7.4; 1.4-37). IgG positive is associated with HCC (OR 2.3; 1.1-4.8) | - |
| Mallet *et al*[36], 2013  | France | R | 267 | Liver | - | - | - | 31% (total; 83/267) | Positive HEV IgG (Wantai assay) | - | - | - | - |
| Pischke *et al*[37], 2014 | Germany | R | 95 | Lung | - | - | - | 5.3% (total; 5/95) | Positive HEV IgG (MP assay) | - | - | - | - |
| Riezebos-Brilman *et al*[38], 2013  | Netherlands | R | 468 | Lung | 40 | 60% | - | 2.1% (total; 10/468) | Positive HEV-RNA | - | 0.4% | - | 6.5 mo |
| Abravanel *et al*[39], 2014  | France | P | 263 | Liver (*n* = 52), kidney (*n* = 211) | 53 | 64.3% | - | 38.4% (total; 101/263). 42.3% for LTx (22/52). 37.4% for KTx (79/211). 1.9% (de novo; 3/162) | Positive HEV IgG, IgM (Wantai assay) or HEV-RNA | - | - | - | 12 mo |
| Buffaz *et al*[40], 2014  | France | R | 206 | Liver | 41.1 | 63.0% | - | 36.4% (total; 75/206). 5.3% (de novo; 11/206) | Positive post-transplant HEV IgG, IgM (Wantai assay) or HEV-RNA | - | - | - | 32.8 mo |
| Riveiro-Barciela *et al*[20], 2014  | Spain | R | 625 | Liver (*n* = 332), kidney (*n* = 296), dual (*n* = 6) | 54.5 | 60.8% | - | 5.8% (total; 36/625). 3.7% (11/296) for KTx. 7.4% (25/332) for LTx | Positive HEV IgG (MP assay) | - | - | Risk factors associated with HEV infection: Cirrhosis (OR 7.6; 4.4-13.1). Liver transplantation (OR 3.1; 1.8-5.4). HIV infection (OR 2.4; 1.3-4.4) | - |
| De Nicola *et al*[41], 2015  | Italy | R | 79 | Liver | 55 | - | - | 33% (total; 26/79). 5.7% (de novo; 3/53) | Positive HEV IgG, IgM (Wantai assay), HEV-RNA | 0% | - | - | 12 mo |
| Magnusson *et al*[42], 2015  | Sweden | P | 62 | Lung | 55 | 37.5% | 100% | 14.8% (total; 8/54). De novo N/A | Positive HEV IgG (recomWell assay) | 25% (2/8) | 17.8% | - | 12 mo |
| Sherman *et al*[43], 2017 | United States | P | 171 | Liver (*n* = 70), kidney (*n* = 101) | - | - | - | 19.9% (total; 34/171). 21.4% (15/70) for LTx. 18.8% (19/101) for KTx | Positive HEV IgG (Wantai assay) | 5.5% (3/55) for LTx. 0% for KTx | - | HIV-infected transplant recipients | 24 mo |
| Erken *et al*[17], 2018  | Netherlands | R | 677 | Kidney | - | - | - | 0.7% (de novo; 2/300) | Positive HEV-RNA | - | - | Subjects are patients with ALT elevations | - |
| Reekie *et al*[18], 2018  | United Kingdom | R | 611 | Liver (*n* = 262), kidney (*n* = 349) | - | - | - | 0.5% (total; 3/611) | Positive HEV-RNA | - | - | - | 36 mo |
| Samala *et al*[44], 2018 | United States | R | 232 | Liver (*n* = 208), kidney (*n* = 10), both *(n* = 10), intestine (*n* = 4) | 58 | 65% | 70% | 19.4% (total; 45/232) | Positive IgG, IgM (Wantai assay) or HEV-RNA | - | - | HEV seroprevalence was associated with older age and patients with the diagnosis of alcohol- or NAFLD-associated liver failure | - |
| Darstein *et al*[45], 2020  | Germany | R | 74 | Liver | 55 | 62.2% | - | 28.8% (total; 21/73) | Positive HEV IgG (recomWell assay) or HEV-RNA | - | - | - | - |
| Komolmit *et al*[46], 2020  | Thailand | P | 108 | Liver | 58 | 69% | 0% | 44% (total; 48/108) | Positive IgG, IgM (Wantai assay) or HEV-RNA | 2% (1/48) | 0.9% | - | 12 mo |
| Wang *et al*[23], 2020  | China | R | 408 | Liver | 50 | 81.1% | 0% | 41.2% (total; 168/408). 16.9% (de novo; 69/408) | Positive HEV-RNA more than 6 months | 13.7% (56/408) | - | Alcoholic cirrhosis (OR 5.324; 1.36-20.98). Liver failure (OR 23.76; 2.78-203.08). Graft rejection (OR 0.217; 0.06-0.74) | 13.7 mo |
| Zanotto *et al*[47], 2020  | Italy | R | 120 | Liver | - | - | - | 19.2% (total; 23/120) | Positive HEV IgG, IgM (N/A assay) or HEV-RNA | - | - | - | - |

UD: Undifferentiated; HEV: hepatitis E virus; LFTs: liver function test; OR: Odds ratio; LTx: Liver transplant; IgG: Immunoglobulin G; MC: Multicenter; IgM: Immunoglobulin M; KTx: Kidney transplant; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; ALT: Alanine aminotransferase; R: Retrospective; NAFLD: Non-alcoholic fatty liver disease; MP: Methylparaben.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**